Biotech Values

[genisi]

Results of ARBITER 6–HALTS Study

This trial doesn't quite put the nail in the coffin for ezetimibe

Would have been the end for Zetia if patients in its arm were to progressed instead of just having no change from baseline. The significantly higher MACE is bad enough. As Taylor commented, Niaspan's superiority answered a key strategic question regarding patients with CV risk already on statin therapy - better to increase their HDL-C levels than to further lower their LDL-C levels. There are two large outcome studies -AIM-HIGH and HPS2-THRIVE due out in 2011 and 2013, that should strengthened niacin use benefits.